JP7148611B2 - Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用 - Google Patents

Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用 Download PDF

Info

Publication number
JP7148611B2
JP7148611B2 JP2020531444A JP2020531444A JP7148611B2 JP 7148611 B2 JP7148611 B2 JP 7148611B2 JP 2020531444 A JP2020531444 A JP 2020531444A JP 2020531444 A JP2020531444 A JP 2020531444A JP 7148611 B2 JP7148611 B2 JP 7148611B2
Authority
JP
Japan
Prior art keywords
bcma
cells
seq
amino acid
chimeric antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020531444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021520185A (ja
Inventor
ウェイ，ユーティアン
ヂュー，リン
リ，ヤンフェン
ヤオ，イーホン
ヤオ，シン
フアン，ジャーチー
チャン，リ
ヂュー，シギュイ
ル，シャオテン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellular Biomedicine Group HK Ltd
Original Assignee
Cellular Biomedicine Group HK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellular Biomedicine Group HK Ltd filed Critical Cellular Biomedicine Group HK Ltd
Publication of JP2021520185A publication Critical patent/JP2021520185A/ja
Priority to JP2021190474A priority Critical patent/JP7299294B2/ja
Application granted granted Critical
Publication of JP7148611B2 publication Critical patent/JP7148611B2/ja
Priority to JP2023098770A priority patent/JP2023116716A/ja
Priority to JP2025051295A priority patent/JP2025098166A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020531444A 2018-04-12 2019-04-02 Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用 Active JP7148611B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021190474A JP7299294B2 (ja) 2018-04-12 2021-11-24 Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用
JP2023098770A JP2023116716A (ja) 2018-04-12 2023-06-15 Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用
JP2025051295A JP2025098166A (ja) 2018-04-12 2025-03-26 Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810326346.9A CN110372796B (zh) 2018-04-12 2018-04-12 靶向bcma的嵌合抗原受体及其制法和应用
CN201810326346.9 2018-04-12
PCT/CN2019/081064 WO2019196713A1 (zh) 2018-04-12 2019-04-02 靶向bcma的嵌合抗原受体及其制法和应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021190474A Division JP7299294B2 (ja) 2018-04-12 2021-11-24 Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用

Publications (2)

Publication Number Publication Date
JP2021520185A JP2021520185A (ja) 2021-08-19
JP7148611B2 true JP7148611B2 (ja) 2022-10-05

Family

ID=68162957

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020531444A Active JP7148611B2 (ja) 2018-04-12 2019-04-02 Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用
JP2021190474A Active JP7299294B2 (ja) 2018-04-12 2021-11-24 Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用
JP2023098770A Pending JP2023116716A (ja) 2018-04-12 2023-06-15 Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用
JP2025051295A Pending JP2025098166A (ja) 2018-04-12 2025-03-26 Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021190474A Active JP7299294B2 (ja) 2018-04-12 2021-11-24 Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用
JP2023098770A Pending JP2023116716A (ja) 2018-04-12 2023-06-15 Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用
JP2025051295A Pending JP2025098166A (ja) 2018-04-12 2025-03-26 Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用

Country Status (9)

Country Link
US (3) US11142581B2 (enExample)
EP (1) EP3778651A4 (enExample)
JP (4) JP7148611B2 (enExample)
KR (1) KR20200142036A (enExample)
CN (3) CN116836297A (enExample)
AU (1) AU2019251016B2 (enExample)
CA (1) CA3095827A1 (enExample)
SG (1) SG11202009962UA (enExample)
WO (1) WO2019196713A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022031784A (ja) * 2018-04-12 2022-02-22 セルラー・バイオメディシン・グループ・エイチケー・リミテッド Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111333732B (zh) * 2019-12-17 2023-02-28 中国药科大学 一种靶向人bcma且激活nk细胞的双特异性抗体的制备及其应用
KR102371151B1 (ko) * 2020-03-13 2022-03-07 주식회사 큐로셀 항-bcma 결합 영역, 이를 포함하는 융합단백질, 및 이를 포함하는 조성물
CN112851815B (zh) * 2020-03-17 2023-08-08 西安宇繁生物科技有限责任公司 抗bcma抗体或其抗原结合片段及其制备方法和应用
CN113527507A (zh) * 2020-04-16 2021-10-22 上海赛比曼生物科技有限公司 靶向cd22的嵌合抗原受体及其制法和应用
CN113637073B (zh) * 2020-05-11 2024-04-12 上海赛比曼生物科技有限公司 Bcma抗体及其制备和应用
CN112251412B (zh) * 2020-10-12 2023-03-28 汤朝阳 一种靶向bcma的嵌合抗原受体t细胞及其应用
CA3201008A1 (en) * 2020-12-02 2022-06-09 Shanghai Cellular Biopharmaceutical Group Ltd. Bcma-targeted chimeric antigen receptors
JP2024500189A (ja) 2020-12-21 2024-01-04 アロジーン セラピューティクス，インコーポレイテッド プロテアーゼ活性化ｃｄ４５ゲートｃａｒ
CN112321713B (zh) * 2020-12-31 2021-05-25 北京艺妙神州医药科技有限公司 一种抗bcma的抗体及其应用
KR20230142470A (ko) 2021-01-29 2023-10-11 알로젠 테라퓨틱스 인코포레이티드 동종이계 세포 산물의 T 세포 인식을 완화하기 위한TAP2, NLRC5, β2m, TRAC, RFX5, RFXAP, 및 RFXANK 중 하나 이상의 녹다운 또는 녹아웃
WO2023167903A2 (en) * 2022-03-01 2023-09-07 Agilent Technologies, Inc. Anti-human b cell maturation antigen (bcma) antibodies and their use in immunohistochemistry (ihc)
US20240042030A1 (en) 2022-07-29 2024-02-08 Allogene Therapeutics, Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition
CN116251188A (zh) * 2023-01-09 2023-06-13 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） Stat1抑制剂在制备b细胞淋巴癌放射增敏药物中的应用及该药物
KR20250131823A (ko) * 2023-03-31 2025-09-03 아벨제타 인크. Cd20 및 bcma를 표적화하는 이중특이적 키메라 항원 수용체
CN116444669B (zh) * 2023-04-04 2024-02-13 科弈(浙江)药业科技有限公司 靶向bcma car-t细胞人源化抗体
WO2025096560A1 (en) 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Engineered cells
CN119119274A (zh) * 2024-09-26 2024-12-13 北京昌盛鸿途生物科技有限公司 一种靶向bcma的cart细胞及其应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014520088A (ja) 2011-05-27 2014-08-21 グラクソ グループ リミテッド Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）結合タンパク質
JP2014534242A (ja) 2011-11-15 2014-12-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ Ｂｃｍａおよびｃｄ３に対する結合分子
WO2016166630A1 (en) 2015-04-13 2016-10-20 Pfizer Inc. Chimeric antigen receptors targeting b-cell maturation antigen
JP2017513478A (ja) 2014-04-14 2017-06-01 セレクティスＣｅｌｌｅｃｔｉｓ 癌免疫療法のためのｂｃｍａ（ｃｄ２６９）特異的キメラ抗原受容体
JP2017522882A (ja) 2014-07-24 2017-08-17 ブルーバード バイオ， インコーポレイテッド Ｂｃｍａキメラ抗原受容体
WO2017211900A1 (en) 2016-06-07 2017-12-14 Max-Delbrück-Centrum für Molekulare Medizin Chimeric antigen receptor and car-t cells that bind bcma
JP2017538710A (ja) 2014-12-12 2017-12-28 ブルーバード バイオ， インコーポレイテッド Ｂｃｍａキメラ抗原受容体
WO2018028647A1 (en) 2015-08-11 2018-02-15 Legend Biotech Usa Inc. Chimeric antigen receptors targeting bcma and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
WO2013154760A1 (en) * 2012-04-11 2013-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting b-cell maturation antigen
GB201503742D0 (en) * 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
AU2016347516A1 (en) * 2015-10-30 2018-05-10 Glaxosmithkline Intellectual Property Development Limited Prognostic method
AU2017244108B2 (en) * 2016-03-29 2021-03-18 University Of Southern California Chimeric antigen receptors targeting cancer
EP3464375A2 (en) 2016-06-02 2019-04-10 Novartis AG Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
CN107827989A (zh) * 2017-10-18 2018-03-23 银丰生物工程集团有限公司 靶向骨髓瘤bcma抗原的转基因t细胞及其制备方法与应用
CN116836297A (zh) * 2018-04-12 2023-10-03 上海赛比曼生物科技有限公司 靶向bcma的嵌合抗原受体及其制法和应用

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014520088A (ja) 2011-05-27 2014-08-21 グラクソ グループ リミテッド Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）結合タンパク質
JP2014534242A (ja) 2011-11-15 2014-12-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ Ｂｃｍａおよびｃｄ３に対する結合分子
JP2015504306A (ja) 2011-11-15 2015-02-12 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ Ｂｃｍａおよびｃｄ３に対する結合分子
JP2017513478A (ja) 2014-04-14 2017-06-01 セレクティスＣｅｌｌｅｃｔｉｓ 癌免疫療法のためのｂｃｍａ（ｃｄ２６９）特異的キメラ抗原受容体
JP2017522882A (ja) 2014-07-24 2017-08-17 ブルーバード バイオ， インコーポレイテッド Ｂｃｍａキメラ抗原受容体
JP2017538710A (ja) 2014-12-12 2017-12-28 ブルーバード バイオ， インコーポレイテッド Ｂｃｍａキメラ抗原受容体
WO2016166630A1 (en) 2015-04-13 2016-10-20 Pfizer Inc. Chimeric antigen receptors targeting b-cell maturation antigen
WO2018028647A1 (en) 2015-08-11 2018-02-15 Legend Biotech Usa Inc. Chimeric antigen receptors targeting bcma and methods of use thereof
WO2017211900A1 (en) 2016-06-07 2017-12-14 Max-Delbrück-Centrum für Molekulare Medizin Chimeric antigen receptor and car-t cells that bind bcma

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022031784A (ja) * 2018-04-12 2022-02-22 セルラー・バイオメディシン・グループ・エイチケー・リミテッド Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用
JP7299294B2 (ja) 2018-04-12 2023-06-27 シャンハイ・セルラー・バイオファーマシューティカル・グループ・リミテッド Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用

Also Published As

Publication number Publication date
JP2022031784A (ja) 2022-02-22
JP2025098166A (ja) 2025-07-01
CA3095827A1 (en) 2019-10-17
AU2023204159A1 (en) 2023-07-20
KR20200142036A (ko) 2020-12-21
SG11202009962UA (en) 2020-11-27
JP7299294B2 (ja) 2023-06-27
AU2019251016A1 (en) 2020-10-22
US20200362048A1 (en) 2020-11-19
CN116514995A (zh) 2023-08-01
US20230053305A1 (en) 2023-02-16
CN110372796A (zh) 2019-10-25
CN110372796B (zh) 2023-05-02
CN116836297A (zh) 2023-10-03
JP2023116716A (ja) 2023-08-22
EP3778651A4 (en) 2022-01-05
WO2019196713A1 (zh) 2019-10-17
US20210403590A1 (en) 2021-12-30
AU2019251016B2 (en) 2023-08-10
JP2021520185A (ja) 2021-08-19
US11142581B2 (en) 2021-10-12
US11498973B2 (en) 2022-11-15
EP3778651A1 (en) 2021-02-17

Similar Documents

Publication Publication Date Title
JP7299294B2 (ja) Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用
JP7578938B2 (ja) Ｂ７－ｈ３に対するモノクローナル抗体および細胞治療におけるその使用
JP7212222B2 (ja) Ｃｄ１９及びｃｄ２０を標的とする組み合わされたキメラ抗原受容体並びにその適用
JP7664657B2 (ja) 二重特異性ｃｓ１－ｂｃｍａ ｃａｒ－ｔ細胞及びその適用
CN113087806A (zh) 靶向多种肿瘤的新型car-t细胞及其制备和方法
JP2023553390A (ja) Ｂｃｍａ標的化キメラ抗原受容体
CN113651893B (zh) 联合her2和meso双靶点car-t载体及其构建方法和在癌症中的应用
US12202896B2 (en) CAR-T cells with humanized CD19 ScFv with mutation in CDR 1 region
CN114853893A (zh) 一种靶向gpc3嵌合抗原受体t细胞及其应用
JP2023521218A (ja) Ｃｄ２２標的キメラ抗原受容体、その調製方法、及びその適用
AU2023204159B2 (en) Bcma-targeted chimeric antigen receptor as well as preparation method therefor and application thereof
HK40077704A (en) Targeted gpc3 chimeric antigen receptor t cell and application thereof
CN115491360A (zh) 一种靶向nkg2d配体和folr1双打靶点car t的制备及应用
CN115572715A (zh) 一种靶向folr1和her2双打靶点car t的制备及应用
HK40044103A (en) Bcma-targeted chimeric antigen receptor as well as preparation method therefor and application thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201117

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20210119

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220805

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220805

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220817

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220823

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220913

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220922

R150 Certificate of patent or registration of utility model

Ref document number: 7148611

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250